Skip to content

Investigating the effect of empagliflozin on the serum level of glycosylated hemoglobin in patients with type 2 diabetes

Investigating the effect of empagliflozin on the serum level of glycosylated hemoglobin in patients with type 2 diabetes

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190618043934N30
Enrollment
45
Registered
2024-11-14
Start date
2024-11-21
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Diabetes mellitus due to underlying condition

Interventions

Intervention group: The number of 45 diabetic patients living in Birjand city will refer to the diabetes clinic and specialized clinic of Valiasr Birjand hospital in 1403..

Sponsors

Birjand University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes Having diabetes for at least 6 months Patients treated with oral medication Glycosylated hemoglobin below 10 and above 8 Previous treatment of the patient with 2 grams of metformin and lack of adequate treatment response

Exclusion criteria

Exclusion criteria: Patients consuming minerals, vitamins or antioxidants or medicinal plants Pregnant or lactating women A patient with heart failure Having a chronic disease such as rheumatology diseases Thyroid problems, whether hypothyroid or hyperthyroid Patients receiving NPH insulin (aspartate, lispro and glargine) and regular Patients with kidney failure, chronic kidney disease (GFR > 30 ml/min), liver failure and patients undergoing treatment for gastrointestinal diseases

Design outcomes

Primary

MeasureTime frame
Fasting Blood Sugar. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: In serum samples of patients using the Bionic company kit.;Glycosylated hemoglobin. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: In serum samples of patients using the Bionic company kit.;Fasting blood sugar 2 hours after eating. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: In serum samples of patients using the Bionic company kit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShaghayesgh Aghasizadeh

Birjand University of Medical Sciences

oabstudent@gmail.com+98 56 3232 3232

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026